IsoRay (ISR) Stock Climbs On Cancer Study Launch

ISR Stock ChartIsoRay, Inc. (NYSEMKT: ISR)

IsoRay shareholders have had an incredible month; and it seems as though the uptrends are just beginning. Today, ISR is climbing even higher on the news that a new cancer study is being launched. So today, we’ll talk about the study and what it means for ISR, how the stock reacted, and what we can expect to see moving forward.

The Study That’s Causing The Climb

Subscribe to The Prudent Speculator

IsoRay is an innovator in brachytherapy and medical isotope applications. In today’s news, they have announced the beginning of a head and neck cancer study. The study, which will take place at the Thomas Jefferson University, will focus on cancer patients that are currently being treated with IsoRay’s Cesium-131 internal radiation cancer seeds. Here’s what Adam Luginbuhl, MD, and one of the investigators of the study had to say…

This study may afford us the opportunity to improve the poor cure rate of patients that develop recurrent head and neck cancer,”

How ISR Reacted In The Market

When we talk about small-cap biotech stocks, we’re talking about an industry where price movements are heavily dependent on news of studies, approvals, acquisitions, and more. The news of this particular study shows that IsoRay is continuing to innovate ways to increase survival rates in those with head and neck cancer; a concept that can prove to be incredibly profitable. So, as we’ve come to expect following such positive news, the value of ISR is climbing today. Currently (12:46), the stock is trading at $1.85 per share after a gain of 8.82% so far today!

What We Can Expect Moving Forward

First off, I’d like to point out that price movements in the market are a series of overreactions. Therefore, we’ll likely see a correction from the highs today. Nonetheless, when we set short term small-cap volatility aside, I’m expecting to see long term gains from ISR. The reality is that cancer is a more than $100 billion per year industry; and if ISR’s study results in a way to improve survival rates in recurring cancers, we can expect the company to take a good chunk of the pie. All in all, I think ISR is definitely moving in the right direction!

What Do You Think?

Where do you think ISR is headed and why? Let us know in the comments below!

Add Comment